Lineage Cell Therapeutics (STU:BT3) Treasury Stock: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:BT3 Lineage Cell Therapeutics Inc STU:BT3
78 GF Score
Price €0.90
GF Value €0.99
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Treasury Stock?

Lineage Cell Therapeutics STU:BT3 -3.64% 78 Treasury Stock is €0.00 Mil as of Jun. 2026. GuruFocus rates STU:BT3 with a GF Score™ of 78/100 and a GF Value™ of €0.99. The stock has 4 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Lineage Cell Therapeutics's treasury stock for the quarter that ended in Jun. 2026 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Lineage Cell Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics Treasury Stock Chart

Lineage Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lineage Cell Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:BT3
78GF Score
Lineage Cell Therapeutics Inc STU:BT3
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lineage Cell Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of €0.00 Mil mean?
Lineage Cell Therapeutics (STU:BT3) has a Treasury Stock of €0.00 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Lineage Cell Therapeutics and its competitors.
Is Lineage Cell Therapeutics' Treasury Stock too high?
Lineage Cell Therapeutics' current Treasury Stock is €0.00 Mil. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Treasury Stock compare to NAGE and IFRX?
Lineage Cell Therapeutics' Treasury Stock of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Lineage Cell Therapeutics and its competitors. Lineage Cell Therapeutics's current Treasury Stock is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Lineage Cell Therapeutics (STU:BT3) has a current Treasury Stock of €0.00 Mil. The stock's GF Value™ is €0.99, compared to a current price of €0.90 — trading 9.2% below its estimated fair value. The current Treasury Stock is €0.00 Mil. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Lineage Cell Therapeutics (STU:BT3), the current Treasury Stock is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (STU:BT3) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of €0.90 is trading 9.2% below its estimated GF Value™ of €0.99.

Key valuation signals for STU:BT3:

  • Treasury Stock: €0.00 Mil
  • GF Value™: €0.99 vs. price of €0.90 (9.2% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the STU:BT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:USALCTX:Israel
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for STU:BT3

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.90
Price
€0.99
GF Value